A review of the trending news in oncology online for the week of December 11, 2020, including recent news from the FDA on the cancer treatment paradigm, updates in oncology, and the latest information regarding COVID-19.
The week of December 11, 2020, has been an exciting week in the field of hematologic malignancies, as well as breast cancer, with 2 medical meetings disseminating important knowledge from clinical trials and key opinion leaders over the last few days. The 2020 Annual Society of Hematology (ASH) Annual Meeting and the 2020 San Antonio Breast Cancer Symposium (SABCS) were held virtually over the last week, and Targeted Oncology covered all the latest updates from these meetings.
The FDA granted a Breakthrough Therapy designation to the KRAS G12C inhibitor sotorasib for the treatment of patients with locally advanced or metastatic non–small cell lung cancer who harbored a KRAS G12C mutation as detected by an FDA-approved test and following at least 1 prior line of systemic therapy.
The combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) demonstrated activity in patients with previously untreated Hodgkin lymphoma who had comorbidities in a phase 2 clinical trial, despite the trial not meeting its prespecified criteria for activity.
Despite having similar disease characteristics and treatment patterns, elderly patients with HER2-positive advanced breast cancer aged ≥ 70 years experienced shorter chemotherapy durations than patients under the age of 70, as well as, poorer overall survival, and increased rates of adverse events in a real-world study.
In an interview with Targeted Oncology, John M. Burke, MD, of Rocky Mountain Cancer Centers, discussed the current treatment paradigm for patients with follicular lymphoma and reviewed the factors he considers when making treatment decisions for this population.
A phase clinical trial has demonstrated that administering a mosunetuzumab fixed-duration lead to high, durable, and consistent responses in patients with follicular lymphoma, across multiple subgroups.
From the 2020 SABCS: Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute, discusses where she sees the treatment landscape evolving in the future for the treatment of patients with hormone receptor-positive metastatic breast cancer.
From the 2020 ASH Annual Meeting: Robert Zeiser, MD, discusses the findings from the phase 3 REACH3 clinical trial of ruxolitinib as treatment of patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.
A research collaboration has identified that patients with hematologic malignancies who are infected with COVID-19 are at greater risk for poor outcomes from the virus.
The COVID-19 pandemic has brought about a currently interminable pause on in-person professional networking.